Current Health announced that it has launched a collaboration with Mayo Clinic to develop remote monitoring solutions that accelerate the identification of COVID-19-positive patients and predict symptom and disease severity in patients, healthcare workers and other at-risk individuals in critical service sectors.
Using digital biomarkers collected by Current Health’s FDA-cleared remote monitoring sensors and platform, experts from Mayo Clinic and Current Health will also be able to expedite identification and assessment of treatment efficacy and improve care for patients with or at risk of COVID-19 infection. Through this collaboration, Current Health and Mayo Clinic aim to improve patient outcomes while preserving and optimizing health system capacity worldwide.
Today, more than 40 hospital systems around the globe use Current Health’s remote patient monitoring platform to monitor and manage patient health. These systems are now increasingly using Current Health to monitor and manage patients infected with COVID-19 at home and in the hospital. The next stage is to use digital biomarkers collected by the Current Health solutions, such as temperature, heart rate, oxygen saturation, activity and posture, to develop AI-based algorithms that can detect and predict symptom and disease severity to enable proactive treatment.
This collaboration will leverage Current Health’s existing patient database – which already includes anonymized vital sign data and raw physiological sensor data from hundreds of patients infected with COVID-19 and thousands of uninfected patients – as well as algorithms developed by Mayo Clinic, which will be used to provide individualized care to patients with complex and critical medical conditions. By working together, Current Health and Mayo Clinic hope to scale data analytics, add to Mayo Clinic’s major advancements in accelerating COVID-19 detection and diagnosis, and further efforts to understand and treat this disease.
“Our collective ability to save lives hinges on our ability to understand this virus quickly. COVID-19 has presented in many ways across different people, which has made it very challenging to understand the virus and how it develops,” said Chris McCann, CEO and Co-Founder, Current Health. “By combining our platform with the deep medical and scientific expertise that exists at Mayo Clinic, we seek to explore both known and novel biomarkers, as well as how they manifest in entirely diverse populations. This will be critical to determining how we define, and enable effective treatment of, this disease.”
“Combatting the COVID-19 pandemic is our number one priority,” said Jordan D. Miller, Ph.D., who directs the Center for Surgical Excellence and leads the investigative team at Mayo Clinic.
“Real-world, continuous data – from patients infected and not infected with the disease – is essential to understanding and predicting how the disease presents and evolves,” says Abinash Virk, M.D., an infectious disease expert at Mayo Clinic. “If we are successful in accomplishing our goals, we believe we will improve how patients with COVID-19 are identified, monitored, managed, and ultimately help with their recovery.”
Mayo Clinic will also become an investor in Current Health as part of this collaboration.